EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter phase-III trial of adjuvant autologous tumor cell-lysate vaccine versus no adjuvant treatment in patients with non-metastasized renal cell carcinoma after radical nephrectomy A 3-year analysis



Multicenter phase-III trial of adjuvant autologous tumor cell-lysate vaccine versus no adjuvant treatment in patients with non-metastasized renal cell carcinoma after radical nephrectomy A 3-year analysis



Journal of Urology 167(4 Supplement): 166-167, April




(PDF 0-2 workdays service: $29.90)

Accession: 035349876

Download citation: RISBibTeXText



Related references

Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Folia Biologica 49(2): 69-73, 2003

Multicenter randomised phase-III trial to compare tumour nephrectomy plus adjuvant autologous tumour cell-lysate vaccine versus tumour nephrectomy without adjuvant treatment for renal cell carcinoma pT2-3bpNO-3M0. European Urology Supplements 2(1): 99, February, 2003

An adjuvant autologous renal tumor cell vaccine reduces the risk of progression in patients with renal cell carcinoma following radical nephrectomy Final results of a multicenter phase-III trial. Journal of Urology 171(4 Supplement): 435, April, 2004

Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Research 23(2a): 969-974, 2003

Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine A 5-year follow-up analysis. Anticancer Research 22(1B): 515, January-February, 2002

Adjuvant therapy of renal cell carcinoma patients with a pure cell-lysate autologous tumor vaccine A 5-year follow-up analysis. Journal of Urology 165(5 Supplement): 187, 2001

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409): 594-599, 2004

Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma, , Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.Lancet 2004;363:594599. Cancer Treatment Reviews 30(6): 589-593, 2004

Adjuvant therapy of renal cell carcinoma with a pure-cell-lysate autologous tumor vaccine A 3-year-follow-up analysis. Proceedings of the American Association for Cancer Research Annual Meeting 39: 367, March, 1998

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633): 145-154, 2008

Adjuvant therapy of renal cell carcinoma with a pure cell-lysate autologous tumor vaccine. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 396, 1997

Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO). Der Urologe. Ausg. A 51(2): 252-253, 2012

AUO (Working Group on Urological Oncology) study of metastasized renal cell carcinoma: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO). Der Urologe. Ausg. A 50(1): 83-84, 2011

Re: ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. European Urology 61(1): 219-220, 2012

Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunology, ImmunoTherapy 59(5): 687-695, 2010